Senior FDA officials at ARDD 2026 outlined how a therapy targeting aging biology might reach approval, confirming that aging and longevity will appear in the agency's forthcoming focus areas of regulatory science document. Two routes were described: demonstrating benefit across several age-related diseases sequentially, or defining a population with multi-domain age-related decline and measuring composite deterioration. Officials expect the earliest approvable trials to use prevention of age-related comorbidities or mortality as endpoints.
Key Points
- FDA will include aging in regulatory science focus areas document
- Earliest approvable endpoints likely comorbidity prevention or mortality
- Officials propose quantifying a shared aging factor across diseases
Longevity Analysis
Regulatory recognition of aging as a measurable, shared contributor to chronic disease shifts the field from lifespan extension in models toward endpoints that can be defended in humans — frailty, cognitive decline, sensory loss, and survival. The proposed shared aging factor, if quantified and validated, would give clinicians a way to interpret decline across cognition, movement, circulation, and immune competence as one signal rather than a collection of separate diagnoses. Until validated surrogates exist, the practical work remains measuring intrinsic capacity consistently over time and acting on what those measurements indicate.
Original published by Longevity.Technology, by Phil Newman.